Diabetes

In the landscape of health care, the year 2023 witnessed remarkable strides in the field of obesity medicine.

BOSTON — In this video, Rohit Loomba, MD, MHSc, discusses data supporting once-monthly dosing of BOS-580, an investigational, long-acting fibroblast growth factor-21 analog for treatment of metabolic dysfunction-associated steatohepatitis.

People with diabetes using a 15-day continuous glucose monitor sensor can now integrate their CGM with an automated insulin delivery system, according to a press release.

Among the newer diagnostics used to quantify diabetic retinal disease, the level of evidence is highest for spectral-domain OCT, suggesting its potential role in an updated classification scheme, according to a literature review.

A form of inhaled insulin has been available for adults with type 1 and type 2 diabetes for nearly a decade, but providers say many people are not aware that it may be a treatment option for them.

Results showed a preoperative blood glucose level greater than 277 mg/dL in patients with diabetes and greater than 193 mg/dL in patients without diabetes was associated with an increased risk of infection after total hip arthroplasty.

Patients with type 2 diabetes and chronic kidney disease receiving empagliflozin were less likely to experience a decline in eGFR compared with patients taking placebo, results from a newly published study show.

The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.

According to a recent study, more than half of the United States population eligible for semaglutide could lose at least 15% of their body weight after treatment with the medication.

The FDA is warning adults with diabetes to avoid using counterfeit semaglutide that may be circulating in the U.S. drug supply chain, according to a press release.